相关临床试验
52
11 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
2014
进行中（未招募）
10
19.2%
已完成
28
53.9%
尚未招募
1
1.9%
招募中
9
17.3%
终止
3
5.8%
撤回
1
1.9%
暂无批准数据
- Atea Pharmaceuticals presented Phase 1 results demonstrating that its hepatitis C virus treatment regimen BEM/RZR has a low risk of drug-drug interactions with commonly used medications including omeprazole and rosuvastatin. - The company's experimental hepatitis E virus treatment AT-587 showed 30 to 150-fold greater potency than existing off-label treatments in preclinical studies, with plans to enter first-in-human trials mid-2026. - These developments address significant unmet medical needs, as approximately 80% of HCV patients take multiple medications concurrently, and there are currently no approved therapies for chronic HEV infections. - AT-587 demonstrated efficacy against drug-resistant strains and showed significant viral load reductions in HEV-infected animal models compared to control groups.
- Atea Pharmaceuticals has completed enrollment of more than 880 treatment-naïve patients in its C-BEYOND Phase 3 trial evaluating bemnifosbuvir and ruzasvir for hepatitis C treatment. - The trial represents the first global Phase 3 head-to-head comparison of direct-acting antivirals, with topline results expected mid-2026. - The investigational regimen offers potential advantages including shorter treatment duration and reduced drug-drug interaction risk compared to current standard of care. - With up to 4 million Americans living with chronic hepatitis C and diagnoses outpacing cure rates, new treatment options could significantly impact patient outcomes.
- Atea Pharmaceuticals reports that patient enrollment remains on track in its global Phase 3 HCV program, with topline results from the North America C-BEYOND trial expected mid-2026. - New research reveals bemnifosbuvir has a unique dual mechanism of action against HCV, inhibiting both viral replication and assembly/secretion of new virions into the bloodstream. - The company announced expansion of its antiviral pipeline with a new hepatitis E virus program featuring two proprietary candidates with potent nanomolar activity against HEV genotypes. - Data presented at The Liver Meeting 2025 support the bemnifosbuvir/ruzasvir combination as a potential best-in-class therapy with high barrier to resistance and flexible dosing options.
• The FDA updated safety information for obeticholic acid (Ocaliva) regarding liver injury risk in primary biliary cholangitis (PBC) patients without cirrhosis. • Breakthrough Therapy designation was granted to tobevibart and elebsiran by the FDA and EMA for chronic hepatitis delta (CHD) treatment, based on Phase 2 SOLSTICE trial data. • Atea Pharmaceuticals reported positive Phase 2 results for bemnifosbuvir and ruzasvir in hepatitis C virus (HCV) treatment, achieving a 98% SVR12 rate. • Belapectin, from Galectin Therapeutics, in MASH cirrhosis and portal hypertension, did not meet its primary endpoint in the Phase 2b/3 NAVIGATE trial.
• Mayo Clinic Arizona found removing _C. difficile_ from gastrointestinal pathogen panels reduced unnecessary treatments and improved diagnostic stewardship. • A _Salmonella_ outbreak linked to cucumbers has sickened 68 people across 19 US states, leading to a product recall by SunFed Produce LLC. • Atea Pharmaceuticals' combination therapy for hepatitis C achieved a 98% SVR12 rate in a Phase 2 trial, paving the way for Phase 3 studies. • Gilead's lenacapavir injection demonstrated high efficacy in preventing HIV infection in Phase 3 trials, leading to NDA submission.
- Atea Pharmaceuticals' Phase 2 study of bemnifosbuvir and ruzasvir for hepatitis C met its primary endpoint, demonstrating a 98% SVR12 rate in treatment-adherent patients. - The combination regimen was generally safe and well-tolerated, with no drug-related serious adverse events or treatment discontinuations reported during the trial. - Atea plans to initiate a global Phase 3 program in early 2025, aiming to simplify the regimen to a two-pill, fixed-dose combination for enhanced patient convenience.
- Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 treatment did not meet its primary endpoint of reducing all-cause hospitalization or death. - The global, randomized, double-blind, placebo-controlled trial involved 2,221 high-risk patients with mild to moderate COVID-19 receiving bemnifosbuvir or placebo. - Bemnifosbuvir was generally safe and well-tolerated in the SUNRISE-3 trial, but the company will not pursue a regulatory pathway forward for COVID-19. - Atea remains focused on developing bemnifosbuvir in combination with ruzasvir for hepatitis C treatment, with additional Phase 2 results expected in Q4 2024.
